FDA conditionally approves Sofdra™ as a trade name for sofpironium bromide
Botanix (ASX: BOT) announced today that the U.S. Food and Drug Administration (FDA) has conditionally approved a trade name for sofpironium bromide gel, 15%. Pending final approval by the FDA, the once-daily topical gel for the treatment of primary axillary hyperhidrosis will be known as Sofdra™. Our team developed trade name options which would satisfy […]